Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report) traded down 15.9% on Wednesday . The stock traded as low as $5.68 and last traded at $5.68. 432 shares were traded during trading, an increase of 2% from the average session volume of 425 shares. The stock had previously closed at $6.75.
Propanc Biopharma Price Performance
The business’s 50-day moving average is $6.64 and its two-hundred day moving average is $2.31.
About Propanc Biopharma
Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.
Further Reading
- Five stocks we like better than Propanc Biopharma
- What Does Downgrade Mean in Investing?
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- Investing in Commodities: What Are They? How to Invest in Them
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- What is the Dow Jones Industrial Average (DJIA)?
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg?v=20230331133551&h=45&w=95&zc=2){kind=logo}
